← Leaderboards
Debra Tonetti
Northwestern University
$2,802,131
Attributed
$2,802,131
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $444.3K · FY2007–11$500K$375K$250K$125K$0
'07
'08
'09
'10
'11
Funding mix
By agency
NIH$2,802,131 · 3
By mechanism
R01$2,466,015 · 2
R21$336,116 · 1
Top collaborators
No co-investigators on record.
Most similar at Northwestern University
Same institution · by research overlap
- Yijun Zhu$2,421,892
- Virgil C Jordan$1,090,907
- Paula H Stern$2,435,050
- James Larry Jameson$8,653,885
- Luisa Iruela-Arispe$34,850,245
Others in their field
Top investigators on “Tamoxifen”
- Norman Wolmark · Nsabp Foundation, Inc.$79,931,398
- Charles A Coltman · Southwest Oncology Group$64,630,528
- Laurence H Baker · University Of Michigan At Ann Arbor$22,633,578
- David Alastair Flockhart · Georgetown University$17,768,070
- Gary K Owens · University Of Virginia$14,826,758
- John L Bryant · University Of Pittsburgh At Pittsburgh$12,247,088
Research focus
TamoxifenHormone TherapyClinical ResearchCell LineGamma SecretaseFutureHormonesAttenuatedAdjuvant TherapyBaseEndocrineEngineeringBiomarkerBreastCancer Stem CellAftercareAromatase InhibitorsBreast Cancer TreatmentCellsChemopreventionDown-RegulationDesignAdjuvantEstrogens
Grant awards (9)
PKC Alpha as a Marker for Logical Therapeutic Approaches to Breast Cancer$425,383
R01 · FY2011 · CA · contact PI
PKC Alpha as a Marker for Logical Therapeutic Approaches to Breast Cancer$439,517
R01 · FY2010 · CA · contact PI
PKC Alpha as a Marker for Logical Therapeutic Approaches to Breast Cancer$443,067
R01 · FY2009 · CA · contact PI
PKC Alpha as a Marker for Logical Therapeutic Approaches to Breast Cancer$420,080
R01 · FY2008 · CA · contact PI
PKC Alpha as a Marker for Logical Therapeutic Approaches to Breast Cancer$444,344
R01 · FY2007 · CA · contact PI
PKC as a Marker in Tamoxifen Resistant Brest Cancer$161,074
R21 · FY2003 · CA
PKC as a Marker in Tamoxifen Resistant Brest Cancer$175,042
R21 · FY2002 · CA
PKC AND TAMOXIFEN-STIMULATED TUMOR GROWTH$148,981
R01 · FY2001 · CA
PKC AND TAMOXIFEN-STIMULATED TUMOR GROWTH$144,643
R01 · FY2000 · CA